Abstract
Oncolytic viruses represent a potentially new treatment for cancer. It is clear, however, that the potency of these agents must be increased, and one approach is to incorporate therapeutic genes that synergise with the lytic functions of the virus. For Ad5, the choice of insertion site(s) is generally limited to a few known non-essential regions for viral DNA replication. Additional less well characterized replication-competent viruses are being developed for cancer therapies, and in these cases extensive research will be needed to characterize insertion sites that are compatible with optimal viral replication. Consequently, we have developed a technology that enables a non-prejudiced scanning of entire viral genomes to identify sites for insertions of transgene expression cassettes without affecting viral replication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
